CO2019001265A2 - Preparacion farmaceutica antienvejecimiento - Google Patents

Preparacion farmaceutica antienvejecimiento

Info

Publication number
CO2019001265A2
CO2019001265A2 CONC2019/0001265A CO2019001265A CO2019001265A2 CO 2019001265 A2 CO2019001265 A2 CO 2019001265A2 CO 2019001265 A CO2019001265 A CO 2019001265A CO 2019001265 A2 CO2019001265 A2 CO 2019001265A2
Authority
CO
Colombia
Prior art keywords
liquid
container
production method
cellular constituents
exosomes
Prior art date
Application number
CONC2019/0001265A
Other languages
English (en)
Inventor
Peter Wehling
Julio Reinecke
Original Assignee
Orthogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/001888 external-priority patent/WO2017080669A1/en
Application filed by Orthogen Ag filed Critical Orthogen Ag
Publication of CO2019001265A2 publication Critical patent/CO2019001265A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/18Antioxidants, e.g. antiradicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invención se relaciona con una preparación farmacéutica para uso en el tratamiento de envejecimiento o como un agente antienvejecimiento, la cual se prepara mediante un método de producción que comprende los siguientes pasos: suministrar un líquido recolectado de un organismo, dicho líquido comprende constituyentes celulares de sangre, y un recipiente o medio de contención, y poner en contacto dicho líquido con dicho recipiente o medio de contención, en donde (i) dicho método de producción además comprende el paso de incubar dicho líquido en dicho recipiente o medio de contención por un tiempo de incubación, y opcionalmente remover los constituyentes celulares de dicho líquido después de dicha incubación, (ii) dicho líquido comprende exosomas, y dicho método de producción además comprende los pasos de concentrar dichos exosomas y opcionalmente remover los constituyentes celulares de dicho líquido después de dicha concentración, o el paso de aislar dichos exosomas, o (iii) dicho método de producción además comprende el paso de evitar la incubación de dicho líquido, y el paso de remover los constituyentes celulares de dicho líquido puesto en contacto con dicho recipiente o medio de contención
CONC2019/0001265A 2016-08-17 2019-02-13 Preparacion farmaceutica antienvejecimiento CO2019001265A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16001807 2016-08-17
PCT/EP2016/001888 WO2017080669A1 (en) 2015-11-13 2016-11-14 Pharmaceutical preparation effective in age-related disorders
PCT/EP2016/001887 WO2017080668A1 (en) 2015-11-13 2016-11-14 Pharmaceutical preparation effective in age-related disorders
PCT/EP2017/000581 WO2018033227A1 (en) 2016-08-17 2017-05-12 Anti-ageing pharmaceutical preparation

Publications (1)

Publication Number Publication Date
CO2019001265A2 true CO2019001265A2 (es) 2019-02-28

Family

ID=61196401

Family Applications (2)

Application Number Title Priority Date Filing Date
CONC2019/0001232A CO2019001232A2 (es) 2016-08-17 2019-02-12 Preparacion farmaceutica antienvejecimiento
CONC2019/0001265A CO2019001265A2 (es) 2016-08-17 2019-02-13 Preparacion farmaceutica antienvejecimiento

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CONC2019/0001232A CO2019001232A2 (es) 2016-08-17 2019-02-12 Preparacion farmaceutica antienvejecimiento

Country Status (21)

Country Link
US (3) US20190290689A1 (es)
EP (4) EP3695845A1 (es)
JP (2) JP2019528281A (es)
KR (2) KR20190049690A (es)
CN (2) CN108348548A (es)
AU (2) AU2017313163B2 (es)
BR (2) BR112019002080A2 (es)
CA (2) CA3033045A1 (es)
CL (2) CL2019000419A1 (es)
CO (2) CO2019001232A2 (es)
CR (2) CR20190139A (es)
EA (2) EA201890841A1 (es)
HK (3) HK1255619A1 (es)
IL (2) IL259007B1 (es)
MA (2) MA42963A (es)
MX (2) MX2019001948A (es)
PE (2) PE20190627A1 (es)
PH (2) PH12019550017A1 (es)
SG (2) SG11201900866YA (es)
TW (2) TW201806605A (es)
WO (3) WO2018033226A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528281A (ja) * 2016-08-17 2019-10-10 オアトゲン アクチエンゲゼルシャフトORTHOGEN Aktiengesellschaft 加齢防止製剤
CN108841784A (zh) * 2018-07-17 2018-11-20 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种含黄芪甲苷的髓核细胞抗衰老抗凋亡培养基
EP3613424A1 (en) 2018-08-23 2020-02-26 Orthogen AG Novel methods for the production of pharmaceutical agents
SG11202105579VA (en) * 2018-12-27 2021-07-29 Suntory Holdings Ltd Agent for inhibiting reduction in decomposition of denatured elastin, agent for maintaining normal elastin fibers, agent for inhibiting formation of elastin-elafine composite, and screening method for substance having elastin-elafine composite formation inhibitory effect
RU2695264C1 (ru) * 2018-12-27 2019-07-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Хакасский государственный университет им. Н.Ф. Катанова" (ФГБОУ ВО ХГУ им. Н.Ф. Катанова) Способ прогнозирования ускоренного старения организма женщин, основанный на клинических данных о состоянии репродуктивной функции

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005262319A1 (en) * 2004-07-01 2006-01-19 Orthogen Ag Immunosuppressive exosomes
DE102006005016A1 (de) * 2006-02-03 2007-08-16 Orthogen Ag Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung
DE202009017772U1 (de) * 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
WO2012076193A1 (de) * 2010-12-10 2012-06-14 Orthogen Ag Kombinationspräparate mit exosomen und corticosteroid
EP3563859B1 (en) * 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
DE102012019088A1 (de) * 2012-09-28 2014-04-03 Orthogen Ag Antibakterielle Arzneimittelpräparate
CN103767985A (zh) * 2012-10-22 2014-05-07 吉林省霍普金斯药物研究院有限责任公司 人源血液或间充质干细胞分泌exosome的制备与应用
KR101784050B1 (ko) * 2014-12-23 2017-10-10 영남대학교 산학협력단 엑소솜을 유효성분으로 함유하는 피부 노화 예방 또는 치료용 약학조성물
CN105477016A (zh) * 2015-11-13 2016-04-13 中国人民解放军第二军医大学 人间充质干细胞来源的外泌体在抗组织纤维化及瘢痕形成中的应用
TW201722443A (zh) * 2015-11-13 2017-07-01 奧爾托金公司 對老化相關病症有效之醫藥製劑
CN105505854B (zh) * 2016-01-14 2019-07-12 上海市第六人民医院 来源于人尿液细胞的外泌体的获取方法与应用
CN105582576B (zh) * 2016-02-23 2018-08-17 武汉大复生物科技有限公司 提高内皮祖细胞外泌体释放并促进骨缺损修复的生物材料、制备方法及用途
JP2019528281A (ja) * 2016-08-17 2019-10-10 オアトゲン アクチエンゲゼルシャフトORTHOGEN Aktiengesellschaft 加齢防止製剤

Also Published As

Publication number Publication date
BR112019002080A2 (pt) 2019-05-14
HK1259143A1 (zh) 2019-11-29
IL259006A (en) 2018-07-31
CA3033045A1 (en) 2018-02-22
SG11201900866YA (en) 2019-02-27
HK1258712A1 (zh) 2019-11-15
JP2019529357A (ja) 2019-10-17
EA201890841A1 (ru) 2018-09-28
BR112019002982A2 (pt) 2019-05-14
EA201890840A1 (ru) 2018-09-28
PE20190627A1 (es) 2019-04-26
EP3352769A1 (en) 2018-08-01
WO2018033226A1 (en) 2018-02-22
KR20190049690A (ko) 2019-05-09
US20210290671A1 (en) 2021-09-23
CN108348548A (zh) 2018-07-31
US20190231816A1 (en) 2019-08-01
CL2019000419A1 (es) 2019-07-05
MX2019001948A (es) 2019-05-15
AU2017313164B2 (en) 2019-01-03
IL259007A (en) 2018-07-31
SG11201901085RA (en) 2019-03-28
AU2017313163B2 (en) 2019-01-03
PH12019550022A1 (en) 2019-12-02
CR20190091A (es) 2019-05-07
WO2018033249A1 (en) 2018-02-22
JP2019528281A (ja) 2019-10-10
PE20190517A1 (es) 2019-04-10
WO2018033227A1 (en) 2018-02-22
CL2019000420A1 (es) 2019-07-05
PH12019550017A1 (en) 2019-11-04
CO2019001232A2 (es) 2019-02-28
CR20190139A (es) 2019-06-03
CN108348549A (zh) 2018-07-31
HK1255619A1 (zh) 2019-08-23
WO2018033227A8 (en) 2019-01-24
TW201806605A (zh) 2018-03-01
AU2017313164A1 (en) 2018-05-10
AU2017313163A1 (en) 2018-05-10
EP3763377A1 (en) 2021-01-13
EP3352770A1 (en) 2018-08-01
EP3695845A1 (en) 2020-08-19
CA3033899A1 (en) 2018-02-22
MX2019001949A (es) 2019-05-15
MA42964A (fr) 2018-08-01
MA42963A (fr) 2018-08-01
KR20190046793A (ko) 2019-05-07
IL259007B1 (en) 2024-03-01
TW201806606A (zh) 2018-03-01
US20190290689A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
CO2019001265A2 (es) Preparacion farmaceutica antienvejecimiento
CL2020002805A1 (es) Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526)
EP4300070A3 (en) Culture patch, culture method, method and apparatus for testing culture, and method and apparatus for testing medicine
ITGE20120034A1 (it) Preparato e metodo per la produzione di un preparato comprendente cellule staminali mesenchimali
CL2015001852A1 (es) Películas de ésteres de poli alfa-1, 3-glucano y metodo para su preparación
MX2013014307A (es) Metodo de tratamiento de celulas madre mesenquinales y su uso en el tratamiento de enfermedades asociadas a estres oxidativo.
AR102198A1 (es) Proceso para reducir partículas subvisibles en una formulación farmacéutica
WO2013036863A3 (en) Efficient use of ionic liquids
IN2014DN07533A (es)
CL2011003102A1 (es) Metodo para tratar solucion organica de extraccion utilizada en extraccion liquido-liquido que comprende etapa de reaccion en la cual solucion de extraccion se pone en contacto con solucion acuosa de hidroxilamina, etapa de separacion y etapa de purificacion por adsorcion de sustancias dañinas de reacciones de re-oximacion, y aparato.
BR112016030758B8 (pt) Uso de células estromais multipotentes derivadas de tecido adiposo mesenquimal
BR112012029472A2 (pt) processo e aparelho para o tratamento eletroquimico de compostos nitroaromáticos, e uso de um aparelho.
BR112014004119A2 (pt) método e dispositivo para produção de cerveja
SG11201811521SA (en) Method for preparing specimen for analysis or observation of skin
MX2017001979A (es) Metodo y aparato in vitro para analizar el comportamiento de sustancias en ambiente fisiologico simulado.
WO2015123192A3 (en) Universal system, method and solution for the acceleration of the process of fixing, dehydrating and clearing the structure of biological tissue
AR100618A1 (es) Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
BR112016006383A8 (pt) métodos para extração de uma proteína solúvel, produção de uma composição e produção de um suporte sólido ou semissólido
ECSP11010747A (es) Tratamiento de madera con creosoto/borato de una sola etapa
EA201591058A1 (ru) Способ приготовления алкоксилированных спиртов
AR101088A1 (es) Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano
MD111Z (ro) Metodă de apreciere a viabilităţii protoscolexurilor echinococului in vitro
AR070462A1 (es) Metodo y composicion para tratar una afeccion diabetica. proceso para preparar dicha composicion. uso.
UA98814U (en) Method for biotin quantitative determination
PL396687A1 (pl) Sposób otrzymywania estru dimetylowego kwasu 4-metylo-4-cyklohekseno-1,2-dikarboksylowego